Liver biopsy in NASH

Prof Bedossa discusses the definition of NAFLD / NASH and the role of liver biopsy. Liver biopsy cannot be used as a screening tool but is essential in clinical trials. To be useful, it has to be of a good quality and optimised. Prof Bedossa shares best practices in this regard.

Read More
The-International-Liver-congress21

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Changes in diet and lifestyle have led to a dramatic increase in the prevalence of NAFLD around the world. This is a meta-analysis of 9 studies, with a cumulative total of 951 participants, looking at the effect of physical activity on liver-specific endpoints: intra-hepatic fat content and serum aminotransferase activities improve.

Read More
The-International-Liver-congress21

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

In an experimental study, S. Lefere et al. investigated the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. The authors employed the CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis. Mice were fed the CDAA-HFD for 12 weeks, and PPAR agonist treatment was administered during the last 6 weeks of diet feeding.

Read More

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Nowadays, dramatic changes in the lifestyle and diet of the global population are causing the prevalence of NAFLD increasing rapidly, in parallel with that of obesity and diabetes. Previous studies found an inverse relationship between physical activity and the risk of NAFLD. However, clinical trials…
Read More

Liver biopsy in NASH by Prof. P. Bedossa

In NAFLD, the liver is both victim and motor of a multisystem disease.
Liver disease is not limited to the liver itself but has an impact on glycemic control in the body.
Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies.

Read More
The-International-Liver-congress21

Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

This meta-analysis of 6 trials using Sodium glucose co-transporter2 (SGLT2) inhibitors to treat type 2 diabetes mellitus reports that SGLT2 inhibitors can significantly decrease alanine amino-transferase ALT and liver fat, accompanying with weight loss, which may have a positive effect on fatty liver in patients with T2DM.

Read More
The-International-Liver-congress21

Awareness of Non-alcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

According to this work, including 7033 subjects for the period of 2001-2016, less than 5% of these patients are aware of having LD. Over the study duration, an increase in BMI, waist circumference, diabetes, and HbA1c; and a decrease in the number of smokers, platelets count, bilirubin, total cholesterol, and LDL level were noticed (p < 0.001). Educational programs to increase awareness of LD and risk factors for NAFLD should be implemented on a large scale.

Read More
The-International-Liver-congress21

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

In this study, J. Boeckmans et al. (Faculty of Medicine and Pharmacy, Vrije Universiteit, Brussels, Belgium) reproduced key NASH characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 hepatic stellate cells to multiple factors that play a role in the onset of NASH.

Read More

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

In this study, J. Boeckmans et al. (Faculty of Medicine and Pharmacy, Vrije Universiteit, Brussels, Belgium) reproduced key NASH characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 hepatic stellate cells to multiple factors that play a role in the onset of NASH…
Read More